Literature DB >> 30416762

Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer.

Masaru Katoh1.   

Abstract

Entities:  

Year:  2018        PMID： 30416762      PMCID： PMC6196211          DOI： 10.21037/jtd.2018.08.123

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  42 in total

Review 1.  Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities.

Authors:  Pablo Perez-Moreno; Elisabeth Brambilla; Roman Thomas; Jean-Charles Soria
Journal:  Clin Cancer Res       Date:  2012-03-08       Impact factor: 12.531

Review 2.  Squamous cell lung cancer: from tumor genomics to cancer therapeutics.

Authors:  David R Gandara; Peter S Hammerman; Martin L Sos; Primo N Lara; Fred R Hirsch
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

Review 3.  New and emerging targeted treatments in advanced non-small-cell lung cancer.

Authors:  Fred R Hirsch; Kenichi Suda; Jacinta Wiens; Paul A Bunn
Journal:  Lancet       Date:  2016-09-01       Impact factor: 79.321

4.  Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

Authors:  Valsamo Anagnostou; Kellie N Smith; Patrick M Forde; Noushin Niknafs; Rohit Bhattacharya; James White; Theresa Zhang; Vilmos Adleff; Jillian Phallen; Neha Wali; Carolyn Hruban; Violeta B Guthrie; Kristen Rodgers; Jarushka Naidoo; Hyunseok Kang; William Sharfman; Christos Georgiades; Franco Verde; Peter Illei; Qing Kay Li; Edward Gabrielson; Malcolm V Brock; Cynthia A Zahnow; Stephen B Baylin; Robert B Scharpf; Julie R Brahmer; Rachel Karchin; Drew M Pardoll; Victor E Velculescu
Journal:  Cancer Discov       Date:  2016-12-28       Impact factor: 39.397

Review 5.  Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.

Authors:  Vassiliki A Boussiotis
Journal:  N Engl J Med       Date:  2016-11-03       Impact factor: 91.245

6.  Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.

Authors:  Cynthia L Gay; Ronald J Bosch; Justin Ritz; Jason M Hataye; Evgenia Aga; Randall L Tressler; Stephen W Mason; Carey K Hwang; Dennis M Grasela; Neelanjana Ray; Josh C Cyktor; John M Coffin; Edward P Acosta; Richard A Koup; John W Mellors; Joseph J Eron
Journal:  J Infect Dis       Date:  2017-06-01       Impact factor: 5.226

7.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

Review 8.  Novel therapeutic targets on the horizon for lung cancer.

Authors:  Wan-Ling Tan; Amit Jain; Angela Takano; Evan W Newell; N Gopalakrishna Iyer; Wan-Teck Lim; Eng-Huat Tan; Weiwei Zhai; Axel M Hillmer; Wai-Leong Tam; Daniel S W Tan
Journal:  Lancet Oncol       Date:  2016-08       Impact factor: 41.316

9.  Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.

Authors:  Gang Chen; Alexander C Huang; Wei Zhang; Gao Zhang; Min Wu; Wei Xu; Zili Yu; Jiegang Yang; Beike Wang; Honghong Sun; Houfu Xia; Qiwen Man; Wenqun Zhong; Leonardo F Antelo; Bin Wu; Xuepeng Xiong; Xiaoming Liu; Lei Guan; Ting Li; Shujing Liu; Ruifeng Yang; Youtao Lu; Liyun Dong; Suzanne McGettigan; Rajasekharan Somasundaram; Ravi Radhakrishnan; Gordon Mills; Yiling Lu; Junhyong Kim; Youhai H Chen; Haidong Dong; Yifang Zhao; Giorgos C Karakousis; Tara C Mitchell; Lynn M Schuchter; Meenhard Herlyn; E John Wherry; Xiaowei Xu; Wei Guo
Journal:  Nature       Date:  2018-08-08       Impact factor: 49.962

10.  The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions.

Authors:  Tong Zhang; Xiaomin Song; Lanlan Xu; Jie Ma; Yanjuan Zhang; Wenfeng Gong; Yilu Zhang; Xiaosui Zhou; Zuobai Wang; Yali Wang; Yingdi Shi; Huichen Bai; Ning Liu; Xiaolong Yang; Xinxin Cui; Yanping Cao; Qi Liu; Jing Song; Yucheng Li; Zhiyu Tang; Mingming Guo; Lai Wang; Kang Li
Journal:  Cancer Immunol Immunother       Date:  2018-04-23       Impact factor: 6.968
View more
  1 in total

1.  Metallothionein 1M (MT1M) inhibits lung adenocarcinoma cell viability, migration, and expression of cell mobility-related proteins through MDM2/p53/MT1M signaling.

Authors:  Wei Xu; Guo-Jun Jiang; Guo-Zhen Shi; Ming-Zhi Chen; Tie-Liang Ma; Yong-Fei Tan
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.